Portugal - inglés - HMA (Heads of Medicines Agencies)

krka d.d. - enrofloxacin 10 g - solution for injection - cattle - enrofloxacin

Rumanía - inglés - HMA (Heads of Medicines Agencies)

krka d.d. - enrofloxacin 10 g - solution for injection - cattle - enrofloxacin

Eslovenia - inglés - HMA (Heads of Medicines Agencies)

krka d.d. - enrofloxacin 10 g - solution for injection - cattle - enrofloxacin

Reino Unido - inglés - HMA (Heads of Medicines Agencies)

krka d.d. - enrofloxacin 10 g - solution for injection - cattle - enrofloxacin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

norbrook laboratories limited - enrofloxacin - solution for injection - 100 milligram(s)/millilitre - enrofloxacin - cattle - antibacterial

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ramipril - oral solution - 500microgram/1ml

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

elanco gmbh - enrofloxacin - oral solution - 2.5 percent weight/volume - enrofloxacin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

elanco gmbh - enrofloxacin - oral solution - 5.0 milligram(s)/millilitre - enrofloxacin

Estados Unidos - inglés - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - valrubicin (unii: 2c6num6878) (valrubicin - unii:2c6num6878) - valrubicin intravesical solution is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of bcg-refractory carcinoma in situ (cis) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. valrubicin intravesical solution is contraindicated in patients with: risk summary based on findings in animal studies and its mechanism of action, valrubicin intravesical solution can cause fetal harm when administered to a pregnant females [see clinical pharmacology (12.1 and 12.3)] . there are no available data in pregnant females to inform the drug-associated risk. in animal reproduction studies, intravenous administration of valrubicin to pregnant rats during the period of organogenesis at a dose about 0.2 times the recommended human intravesical dose caused embryo-fetal malformations and increased resorptions [see data] . advise females who are or might become pregnant of the potential risk to a fetus. in the u.s. general p

Estados Unidos - inglés - NLM (National Library of Medicine)

endo pharmaceuticals solutions inc. - valrubicin (unii: 2c6num6878) (valrubicin - unii:2c6num6878) - valrubicin 40 mg in 1 ml - valstar is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of bcg-refractory carcinoma in situ (cis) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. valstar is contraindicated in patients with: - perforated bladder [ see warnings and precautions ( 5.2)] - known hypersensitivity to anthracyclines or polyoxyl castor oil - active urinary tract infection - small bladder capacity and unable to tolerate a 75 ml instillation risk summary based on findings in animal studies and its mechanism of action, valstar can cause fetal harm when administered to a pregnant females [see clinical pharmacology ( 12.1and 12.3)] .  there are no available data in pregnant females to inform the drug-associated risk.  in animal reproduction studies, intravenous administration of valrubicin to pregnant rats during the period of organogenesis at a dose about 0.2 times the recommended human intr